Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome

• Main Authors: Khaled Abd Elaziz Ahmed Elnaghi (Author), Hosam Ali Alghanmi (Author), Shereef Ahmed Elsamany (Author), Fathia Almarzoki (Author), Mohamed Elsafty (Author), Mohammad Jaffal (Author)
• Format: Book
• Published: Hindawi-Wiley, 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background. CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological...